Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) EPS (Weighted Average and Diluted) (2016 - 2025)

Cumberland Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 16 years, with the latest figure at -$0.09 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 35.71% year-over-year to -$0.09; the TTM value through Dec 2025 reached -$0.19, up 59.57%, while the annual FY2025 figure was -$0.19, 58.7% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.09 at Cumberland Pharmaceuticals, up from -$0.13 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.08 in Q2 2021 and bottomed at -$0.29 in Q4 2021.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.08 (2024), against an average of -$0.07.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 233.33% in 2021 against a maximum downside of 2800.0% in 2021.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.29 in 2021, then skyrocketed by 41.38% to -$0.17 in 2022, then soared by 58.82% to -$0.07 in 2023, then plummeted by 100.0% to -$0.14 in 2024, then surged by 35.71% to -$0.09 in 2025.
  • Per Business Quant, the three most recent readings for CPIX's EPS (Weighted Average and Diluted) are -$0.09 (Q4 2025), -$0.13 (Q3 2025), and -$0.05 (Q2 2025).